These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
740 related articles for article (PubMed ID: 17224152)
1. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Bayrak A; Terbell H; Urwitz-Lane R; Mor E; Stanczyk FZ; Paulson RJ Fertil Steril; 2007 Apr; 87(4):870-5. PubMed ID: 17224152 [TBL] [Abstract][Full Text] [Related]
2. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325 [TBL] [Abstract][Full Text] [Related]
3. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. Kriplani A; Agarwal N J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709 [TBL] [Abstract][Full Text] [Related]
4. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Nardo LG; Yates AP; Roberts SA; Pemberton P; Laing I Hum Reprod; 2009 Nov; 24(11):2917-23. PubMed ID: 19617605 [TBL] [Abstract][Full Text] [Related]
5. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Kazerooni T; Dehghan-Kooshkghazi M Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019 [TBL] [Abstract][Full Text] [Related]
6. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Nascimento AD; Silva Lara LA; Japur de Sá Rosa-e-Silva AC; Ferriani RA; Reis RM Gynecol Endocrinol; 2013 Mar; 29(3):246-9. PubMed ID: 23194004 [TBL] [Abstract][Full Text] [Related]
7. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases]. Song J; Shen H; Li J; Huang Z; Zhang Y Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071 [TBL] [Abstract][Full Text] [Related]
8. Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? Muttukrishna S; Suharjono H; McGarrigle H; Sathanandan M BJOG; 2004 Nov; 111(11):1248-53. PubMed ID: 15521870 [TBL] [Abstract][Full Text] [Related]
9. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Wu J; Zhu Y; Jiang Y; Cao Y Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522 [TBL] [Abstract][Full Text] [Related]
10. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fleming R; Harborne L; MacLaughlin DT; Ling D; Norman J; Sattar N; Seifer DB Fertil Steril; 2005 Jan; 83(1):130-6. PubMed ID: 15652898 [TBL] [Abstract][Full Text] [Related]
11. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354 [TBL] [Abstract][Full Text] [Related]
12. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364 [TBL] [Abstract][Full Text] [Related]
13. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B. Chu MC; Carmina E; Wang J; Lobo RA Fertil Steril; 2005 Dec; 84(6):1685-8. PubMed ID: 16359965 [TBL] [Abstract][Full Text] [Related]
14. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Ozkaya M; Cakal E; Ustun Y; Engin-Ustun Y Fertil Steril; 2010 Feb; 93(3):880-4. PubMed ID: 19111298 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Sönmez AS; Yasar L; Savan K; Koç S; Ozcan J; Toklar A; Yazicioğu F; Akgün A; Sut N Hum Reprod; 2005 Jan; 20(1):175-9. PubMed ID: 15513975 [TBL] [Abstract][Full Text] [Related]
16. [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome]. Liu ZA; Xue YM; Chen LX; Cai Q; Chen H; Zhang J; Cui QH; Ge J; Yuan T Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):586-90. PubMed ID: 15498183 [TBL] [Abstract][Full Text] [Related]
17. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? Muttukrishna S; McGarrigle H; Wakim R; Khadum I; Ranieri DM; Serhal P BJOG; 2005 Oct; 112(10):1384-90. PubMed ID: 16167941 [TBL] [Abstract][Full Text] [Related]
18. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765 [TBL] [Abstract][Full Text] [Related]
19. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age]. Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740 [TBL] [Abstract][Full Text] [Related]
20. Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients. Aleyasin A; Aghahoseini M; Mokhtar S; Fallahi P Acta Med Iran; 2011; 49(11):715-20. PubMed ID: 22131240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]